We finally tested the therapeutic effects of Rebastinib on pre-existing CCMs in a severe model, i.e., Ccm3 deletion at P1 followed by administration of the inhibitor at P15 when the CCM lesion fully bloomed (Fig. 9a). The gene discussed is PDCD10; the disease is cerebral cavernous malformation.